Table 2 Prespecified adverse event preferred terms, MedDRA version 12.1

Endophthalmitis

Drug hypersensitivity

Panophthalmitis

Hypersensitivity

Intraocular pressure, increased

Hypersensitivity NOS (v. 5.1)

Ocular hypertension

Anaphylactic shock

Glaucoma

Anaphylactic reaction

Glaucoma NOS (v. 5.1)

Anaphylactoid shock

Glaucoma, traumatic

Anaphylactoid reaction

Retinal injury

Angioedema

Retinal tear

Angioneurotic edema (v. 5.1)

Retinal detachment

Blepharitis, allergic

Retinal hemorrhage

Dermatitis, contact

Retinal toxicity

Dermatitis, allergic

Detachment of retinal pigment epithelium

Toxic skin eruption

Retinal pigment epitheliopathy (v. 5.1)

Toxic epidermal necrolysis

Eye hemorrhage

Lyell syndrome (v. 5.1)

Eye hemorrhage NOS (v. 5.1)

Drug eruption

Vitreous hemorrhage

Dermatitis medicamentosa (v. 5.1)

Cataract traumatic

Erythema

Erythema multiforme

Urticaria

Tongue edema

Stevens-Johnson syndrome

Pharyngeal edema

Stevens-Johnson syndrome (v. 5.1)

Laryngeal edema

Rash

Latex allergy

Rash NOS (v. 5.1)

Paresthesia oral

Skin reaction

Paraesthesia mucosal

Acute generalized exanthematous pustulosis

Paraesthesia mucosal NOS (v. 5.1)

Drug rash with eosinophilia and systemic symptoms

Antiplatelet Trialists’ Collaboration Events

Cardiovascular

Cerebrovascular

Acute myocardial infarction

Brain stem infarction

Cardiac arrest

Cerebrovascular accident

Cardiac failure congestive

Lacunar infarction

Myocardial infarction

Cerebral hemorrhage

Retroperitoneal hemorrhage

Transient ischemic attack

Sudden death

Peripheral vascular thrombosis

Silent myocardial infarction

Pulmonary embolism

Coronary artery stenosis

Deep vein thrombosis

Acute coronary syndrome

Thrombosis

Angina pectoris

Ischemia

Angina unstable

Ischemia NOS (v. 5.1)